This article is for educational and research purposes only. Nothing here constitutes medical advice. Consult a licensed healthcare provider before using any peptide.
What Is Hexarelin?
Hexarelin (examorelin) is a synthetic hexapeptide growth hormone secretagogue and one of the most potent GH-releasing peptides ever developed. Structurally derived from GHRP-6 with modifications that enhance receptor binding and GH release, hexarelin was developed in the 1990s and has been the subject of extensive clinical research, including human studies in various populations. On a per-dose basis, hexarelin produces greater GH release than GHRP-6, GHRP-2, or ipamorelin, making it the strongest GHRP in its class.
Beyond GH secretion, hexarelin has attracted research interest for its direct cardioprotective properties — effects that appear to be independent of GH release and mediated through a separate receptor pathway (CD36).
Mechanism of Action
Hexarelin exerts its effects through two distinct receptor systems:
- GHSR-1a activation: Like other GHRPs, hexarelin binds to the growth hormone secretagogue receptor type 1a on pituitary somatotrophs, triggering robust GH release. It produces the highest peak GH response of any synthetic GHRP in head-to-head comparisons.
- CD36 receptor activation: Hexarelin uniquely binds to CD36 (scavenger receptor class B), a multifunctional receptor involved in lipid metabolism, angiogenesis, and cardiac protection. This interaction appears to mediate direct cardioprotective effects independent of GH release — a property not shared by ipamorelin or other selective GHSRa agonists.
- Cortisol and prolactin elevation: Unlike ipamorelin, hexarelin significantly elevates cortisol and prolactin at GH-releasing doses. This is a consequence of its potent but less selective GHSR activation profile. The prolactin elevation limits its use in long-term protocols compared to more selective agents.
Clinical Research
Human studies with hexarelin have demonstrated robust GH-releasing activity. Single-dose studies show peak GH responses of 50-80 ng/mL — substantially higher than the 20-40 ng/mL typically seen with ipamorelin or GHRP-2 at equivalent doses. However, chronic dosing studies revealed a significant limitation: GH response to hexarelin diminishes substantially after 4-16 weeks of continuous use, suggesting receptor desensitization or tachyphylaxis.
The cardioprotective research is perhaps more unique. Studies by Bhatt et al. demonstrated that hexarelin protected isolated cardiomyocytes from ischemia-reperfusion injury. Animal studies showed reduced infarct size and improved cardiac function after coronary artery occlusion. These effects persisted in GH-deficient animal models, confirming they are GH-independent. Human studies in patients with cardiac dysfunction showed improved cardiac output and reduced systemic vascular resistance.
Dosing Protocols
- Standard GH-release dose: 100-200 mcg per injection, administered subcutaneously
- Frequency: 1-3 times daily
- Cycle length: Due to desensitization, cycles are typically limited to 4-8 weeks with equal off-periods
- Cardioprotective research: Lower doses may be sufficient for cardiac benefits mediated through CD36
The Bottom Line
Hexarelin is the most potent GH-releasing peptide available, producing the highest peak GH responses in human studies. Its unique cardioprotective properties via CD36 activation add a therapeutic dimension not found in other secretagogues. However, its tendency toward desensitization with chronic use, and its elevation of cortisol and prolactin, make it less suitable for long-term GH optimization compared to more selective agents like ipamorelin. It is best considered a short-term, high-potency tool rather than a maintenance peptide. It has no regulatory approval for any clinical indication.